1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
DuoGenic StemCells Corporation

DuoGenic StemCells Corporation

TTPEX:7607
8.57
TWD
+0.07
(+0.82%)
498.48MMarket Cap
DuoGenic StemCells Corporation
TPEX:7607
(Taipei Exchange)

Recent

price

8.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
TWD
0.09
0.24
0.45
0.39
0.65
- -
Revenue per Share
-0.86
-1.18
-1.5
-2.02
-0.83
- -
Basic EPS, GAAP
-1.13
-1.58
-1.48
-1.59
-0.59
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
2.28
2.41
2.57
0.55
1.43
1.14
Book Value per Share
2.24
2.33
2.51
0.52
1.42
1
Tangible Book Value per Share
26
29
30
31
32
35
Basic Weighted Avg Shares
2
7
14
12
21
- -
Sales/Revenue/Turnover
-1,007.49
-488.53
-328.42
-506.23
-124.65
- -
Operating Margin (%)
3
5
7
7
6
- -
Depreciation Expense
-22
-34
-45
-62
-26
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-956.9
-496.21
-330.99
-510.94
-127.48
- -
Profit Margin (%)
53
48
56
-1
33
27
Working Capital
1
2
5
4
1
4
LT Debt
70
74
78
17
51
42
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-47.53
-59.51
-129.28
-77.78
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
31
21
23
LT Borrowings
- -
- -
3
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
36
37
Market Capitalization
326
656
498

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
41
59
58
Cash, Cash Equivalents & STI
31
50
33
Accounts Receivable, Net
2
4
5
Inventories
4
2
12
Total Current Liabilities
38
26
31
Payables & Accruals
- -
- -
- -
ST Debt
31
21
23
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
202.73%
Free Cash Flow
- -
- -
-61.41%
Net Income, GAAP
- -
- -
-57.16%
Sales/Revenue/Turnover
- -
- -
71.7%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
12
2025
- -
- -
21
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.02
2025
- -
- -
-0.83
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
DuoGenic StemCells Corporation is actively involved in the biotechnology and medical care industries, with a strong focus on regenerative medicine and advanced cell therapy applications. The company develops and provides specialized xeno-free stem cell culture media for both research and clinical use, along with integrated closed-system cell culture technologies designed to enhance scalability and reduce costs. Additionally, DuoGenic pioneers blood cell therapy initiatives, including its Peripheral Blood Cell Purification (PCP) approach for managing degenerative conditions such as osteoarthritis. Founded on March 22, 2018, the company is headquartered in Taichung, Taiwan, and is dedicated to advancing the accessibility and widespread adoption of cell therapy.